Court of Justice 25 February 2010, C-66/09 (Kirin Amgen Inc. v Lietuvos Respublikos valstybinis patentų biuras.)

Opinion of the Advocate-General Opinion of the Advocate-General 1. A pharmaceutical undertaking which is the holder of a patent for a medicinal product and which is also authorised to place that product on the market may benefit from an extension of the period of its exclusive rights as a result of the award of a ‘supplementary protection certificate’, the grant of which, in each of the Member